FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGE</b>	ES IN BENEFI	CIAL OWNE	RSHIP

OMB APF	PROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	e: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Si	ee Instruction	on 10.																		
Name and Address of Reporting Person*     Shareling O. Lawrence				2. Issuer Name <b>and</b> Ticker or Trading Symbol bluebird bio, Inc. BLUE							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
Sterling O. James					block j									ector		10% Ov				
														_		icer (give title ow)		Other (s	specify	
(Last)		(First	A) (N	/liddle)			3. Date of Earliest Transaction (Month/Day/Year)								— Бе	- /		, ,		
C/O BLUEBIRD BIO, INC					09/3	09/30/2024									Chief Financial Officer					
455 GRAND UNION BOULEVARD																				
				4. If Amendment, Date of Original Filed (Month/Day/Year)							6.	6. Individual or Joint/Group Filing (Check Applicable								
(Street)						1										Line)				
SOMER	VILLE	MA	0:	2145		1										Form filed by One Reporting Person				on
						1										Form filed by More than One Reporting Person				
(City)		(State	e) (Z	(ip)												10	3011			
(0.1,7)		(01011	(=																	
			Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or I	Ben	eficia	ally Ow	ned			
1. Title of	Security (	nstr.	3)		2. Transac	tion								nount of			7. Nature			
	•		,		Date (Month/Da	Execution Date,			Transaction Disposed Of (D) (Instr. 3 Code (Instr. 5)			3, 4 an		ırities eficially			of Indirect Beneficial			
(months 2d)			, ,	(Month/Day/Year) 8)						Own	ed Following		(Instr. 4)	Ownership (Instr. 4)						
						Code	v	Amount	(A)	) or )	Price	Tran	Transaction(s) (Instr. 3 and 4)			(11150.4)				
								_		+			<u> </u>		-					
Common	Stock <sup>(1)</sup>				09/30/2	2024			A		100,000		A	\$0.0	0	100,000		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
			Tuk									onvertib					- Cu			
1. Title of 2. 3. Transaction 3A. Deemed 4.								5 Nu	ımber	6 Date	Fyerc	isable and	7 Tit	tle and	1	8. Price o	f 9. Number	of .	10.	11. Nature
Derivative Conversion			Date	Executi	ion Date,	ate, Transa		of		Expiration Date		ite	Amount of			Derivativ	e derivative	·	Ownership	of Indirect
(Instr. 3)	Security or Exercise (Month/Day/Year) if any (Instr. 3) Price of (Month/Day/Year)			/Day/Year)	Code (   8)	Code (Instr. 8)		Derivative Securities					Securities Underlying		Security (Instr. 5)	Securities Beneficial		Form: Direct (D)	Beneficial Ownership	
, ,	Derivative Security	•		ľ		,		Acquired		Derivat Securit						Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)	
	Security								(A) or Disposed of (D) (Instr. 3, 4		3 and						Reported			
																	Transactio	n(s)		
								and 5)									` ′			
													Amou		ount					
														or Nur	nber					
						Code V		(A) (D)		Date Exercisable		Expiration Date	of Title Sh		res					
		L						1,,				- 3.0		1						

## **Explanation of Responses:**

1. These restricted stock units for common stock vest over a four-year period at the rate of 25% on each of July 1, 2025, July 1, 2026, July 1, 2027 and July 1, 2028.

## Remarks:

/s/ Sydney Gaylin, Attorney-

10/02/2024

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

With respect to holdings of and transactions in securities issued by bluebird bio, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities
  Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule
  144 ("Form 144"), in accordance with the requirements of Rule
  144 under the Securities Act of 1933, as amended (the "Securities Act"); and
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this  $\_\_$  day of May, 2024.

O. James Sterling Schedule A

INDIVIDUALS APPOINTED AS ATTORNEY-IN-FACT, WITH FULL POWER OF SUBSTITUTION AND RESUBSTITUTION

- 1. Andrew Obenshain
- 2. Joseph Vittiglio
- 3. Sydney Gaylin